retatrutide triple agonist glp-1 gip glucagon phase 2 obesity trial is gaining attention in metabolic research for its activity on GIP, GLP-1, and receptors. In this carousel, we summarize recent clinical study findings related to weight management, type Retatrutide Triple Agonist Research Peptide

It contains a combination of amphetamine and dextroamphetamine

The first month serves as a dose-titration phase, where your dose may need to go up gradually to minimize side effects and optimize results

In addition, a representative from the American Association of Clinical Endocrinology (AACE) (GEU) was appointed to the taskforce

It remains an uncommon but serious potential risk

Recent pharmacovigilance has also identified signals for intestinal obstruction (ileus) with some GLP-1 receptor agonists

Jindal AB, Bhide AR, Salave S et al (2023) Long-acting parenteral drug delivery systems for the treatment of chronic diseases